Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Methods for evaluating chondroprotective agents]

M Lequesne

    Revue Du Rhumatisme (Ed. Francaise : 1993)
    |November 15, 1994
    PubMed
    Summary
    This summary is machine-generated.

    Chondroprotective compounds show promise in lab studies but lack convincing human evidence for osteoarthritis. Clinical trials need to focus on cartilage lesion progression over 2-4 years using specific measurement methods.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinical and MRI results in 67 patients operated for gluteus medius and minimus tendon tears with a median follow-up of 4.6 years.

    Orthopaedics & traumatology, surgery & research : OTSR·2014
    Same author

    [Systemic lupus erythematosus].

    Revue medicale de France·2014
    Same author

    [Treatment of chronic rheumatoid polyarthritis; its history--its current status].

    Revue medicale de France·2014
    Same author

    Descriptive epidemiology of mechanical hip pathology in adults under 50 years of age. Prospective series of 292 cases: Clinical and radiological aspects and physiopathological review.

    Orthopaedics & traumatology, surgery & research : OTSR·2010
    Same author

    Imaging data in a prospective series of adult hip pain in under-50 year-olds.

    Orthopaedics & traumatology, surgery & research : OTSR·2010
    Same author

    Gluteal tendinopathy in refractory greater trochanter pain syndrome: diagnostic value of two clinical tests.

    Arthritis and rheumatism·2008
    Same journal

    Revue du rhumatisme (Ed. francaise : 1993)·2022
    Same journal

    Revue du rhumatisme (Ed. francaise : 1993)·2022
    Same journal

    Revue du rhumatisme (Ed. francaise : 1993)·2022
    Same journal

    Revue du rhumatisme (Ed. francaise : 1993)·2022
    Same journal

    Revue du rhumatisme (Ed. francaise : 1993)·2022
    Same journal

    Mécanisme d'action du méthotrexate dans le traitement de la polyarthrite rhumatoïde.

    Revue du rhumatisme (Ed. francaise : 1993)·2022
    See all related articles

    Area of Science:

    • Orthopedics
    • Rheumatology
    • Pharmacology

    Background:

    • Compounds exhibiting chondroprotective effects are documented in animal and chondrocyte models.
    • However, robust clinical evidence demonstrating efficacy in preventing or repairing human osteoarthritis cartilage lesions is lacking.

    Purpose of the Study:

    • To outline essential criteria for clinical trials evaluating chondroprotective agents in osteoarthritis.
    • To emphasize the importance of accurately measuring cartilage lesion progression and assessing clinical benefits.

    Main Methods:

    • Recommends cartilage thickness measurement (compasses, magnifying glass) or joint space surface area analysis of digitalized images.
    • Suggests intraarticular ultrasound probe during arthroscopy for echotomographic sections.
    • Discourages external MRI and ultrasonography due to validation challenges.

    Related Experiment Videos

    Main Results:

    • Cartilage loss in osteoarthritis is slow, necessitating 2-4 year trial durations.
    • Mean annual cartilage loss rates vary, reported around 1/4 mm at hip and knee.
    • Clinical assessment of therapeutic benefits is crucial for evaluating chondroprotection.

    Conclusions:

    • Clinical trials for chondroprotective drugs in osteoarthritis require a focus on structural cartilage lesion changes over extended periods.
    • A randomized, double-blind, placebo-controlled design is recommended for rigorous evaluation.
    • Integrating structural and clinical outcome measures is vital for validating therapeutic benefits.